RxDoctor Payments Data

Rachel Matthews, NP

Family · Coronado, CANPI 1841758182

Payments from drug & device makers

$1,221in general payments, 2019–2025

Across 53 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$263
  • Eisai Inc.$144
  • Sanofi-aventis U.S. LLC$128
  • Novartis$123
  • Boehringer Ingelheim$95
  • GSK$87
  • plus $379 from 12 others

What the payments were for

  • Food & beverage$1,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,221 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$38,516
Medicare patients
224
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$50,035
Rosuvastatin Calcium78$1,246
Levothyroxine Sodium41$799
Gabapentin41$585
Atorvastatin Calcium46$505
Famotidine21$420
Montelukast Sodium21$413
Losartan Potassium28$351
Escitalopram Oxalate19$263
Fluticasone Propionate16$256
Metformin Hcl ErMetformin Hcl13$255
Albuterol Sulfate HfaAlbuterol Sulfate12$253
Amlodipine Besylate44$239
Omeprazole13$219
Lisinopril33$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$50,03525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Coronado

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →